Five studies on breast, colon and colorectal cancer to be presented at ASCO Annual Meeting

Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31-June 4, 2013 at McCormick Place in Chicago. Of particular importance are the studies which demonstrate that molecular subtyping allows for improvement in therapy selection and overall patient survival. 

The posters covering breast cancer include:

• Effectiveness of MammaPrint^® and BluePrint^® in identifying molecular subtypes of breast tumors as a predictor for tumor response to targeted chemotherapies.
• MammaPrint MINT study assesses the ability of molecular profiling and traditional pathologic and clinical prognostic factors to predict patient response to neo-adjuvant chemotherapy.
• Genomic profiling of breast cancer in African American women.

"It is clear that molecular subtypes are key pieces of information in determining the best course of treatment for breast cancer patients, and that subtyping will only become more important as hundreds of targeted therapies reach the market in the coming decade," said Agendia CEO David Macdonald .

The posters/discussions covering colorectal and colon cancer include:

• Intrinsic subtypes of colorectal cancer that direct different treatment strategies.
• The use of ColoPrint^® as a predictor of outcome and chemotherapy benefit in stage II and III colon cancer patients.

"Like breast cancer, where molecular classification into subtypes has clear relevance for prognosis and treatment, we are finding clinically relevant subtypes for colorectal and colon cancer," Macdonald added. "Agendia has a rich history of presenting innovative and ground-breaking research that benefits oncologists and their cancer patients."